within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC01_Cytarabine;

model Cytarabine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.0222222222222222e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0007700000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00035999999999999997,
    k12 = 2.7027777777777778e-05,
    k21 = 2.7027777777777778e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cytarabine</td></tr><tr><td>ATC code:</td><td>L01BC01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.77</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.04</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cytarabine (also known as Ara-C) is a cytosine nucleoside analog used primarily as an antimetabolite chemotherapy agent for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma. It inhibits DNA synthesis in rapidly dividing cells. Cytarabine is an approved and widely used chemotherapy drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adults with acute myeloid leukemia treated via intravenous infusion; values reflect population pharmacokinetics.</p><h4>References</h4><ol><li><p>Mancini, SL, et al., &amp; Messenger, KM (2022). Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology. <i>American journal of veterinary research</i> 83(9) –. DOI:<a href=\"https://doi.org/10.2460/ajvr.22.03.0046\">10.2460/ajvr.22.03.0046</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35895763/\">https://pubmed.ncbi.nlm.nih.gov/35895763</a></p></li><li><p>Feldman, EJ, et al., &amp; Plezia, P (1993). Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 11(10) 2002–2009. DOI:<a href=\"https://doi.org/10.1200/JCO.1993.11.10.2002\">10.1200/JCO.1993.11.10.2002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8410125/\">https://pubmed.ncbi.nlm.nih.gov/8410125</a></p></li><li><p>Periclou, AP, &amp; Avramis, VI (1996). NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. <i>Cancer chemotherapy and pharmacology</i> 39(1-2) 42–50. DOI:<a href=\"https://doi.org/10.1007/s002800050536\">10.1007/s002800050536</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8995498/\">https://pubmed.ncbi.nlm.nih.gov/8995498</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01BC01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cytarabine;
